Insider Stock Trading History of Altomari Alfred


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Altomari Alfred since year 2005. The trader's CIK number is 1285644. At the time of this reporting, Altomari Alfred is the Chairman & Chief Executive Off of Agile Therapeutics Inc . (stock ticker symbol AGRX). See this page for all insider trading activities at Agile Therapeutics Inc .

Note that in the past ALTOMARI ALFRED also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Altomari Alfred since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-08-25 AGRX Agile Therapeutics Inc Buy 10,000 3.34 33,400
2017-05-11 AGRX Agile Therapeutics Inc Buy 10,000 3.51 35,100
2017-04-11 AGRX Agile Therapeutics Inc Option Ex 30,000 1.76 52,800
2017-02-08 AGRX Agile Therapeutics Inc Option Ex 16,667 .00 0
2016-12-15 REPH Recro Pharma, Inc. Buy 1,500 6.55 9,825
2016-02-08 AGRX Agile Therapeutics Inc Option Ex 16,666 .00 0
2015-06-02 AGRX Agile Therapeutics Inc Buy 2,500 8.73 21,825
2015-03-11 AGRX Agile Therapeutics Inc Option Ex 17,500 1.76 30,800
2014-12-18 AGRX Agile Therapeutics Inc Option Ex 30,000 1.76 52,800
2014-01-11 INSM Insmed Inc Option Ex 8,955 .00 0
2013-08-02 INSM Insmed Inc Option Ex 4,327 .00 0
2011-08-11 DUSA Dusa Pharmaceuticals Inc Buy 2,000 4.06 8,119
2010-08-05 DUSA Dusa Pharmaceuticals Inc Buy 2,000 2.52 5,040
2007-05-08 AUXL Auxilium Pharmaceuticals Inc Option Ex 15,000 6.06 90,900
2007-05-08 AUXL Auxilium Pharmaceuticals Inc Sale 15,000 13.33 199,890

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Altomari Alfred (Chairman & Chief Executive Off of Agile Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.